Inovio PharmaceuticalsINO
About: Inovio Pharmaceuticals Inc is a United States-based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Employees: 122
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
48% more call options, than puts
Call options by funds: $2.93M | Put options by funds: $1.98M
36% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 22
14% more capital invested
Capital invested by funds: $57.2M [Q1] → $65.1M (+$7.88M) [Q2]
13.44% more ownership
Funds ownership: 17.66% [Q1] → 31.1% (+13.44%) [Q2]
9% more funds holding
Funds holding: 88 [Q1] → 96 (+8) [Q2]
5% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 20
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
RBC Capital Gregory Renza 56% 1-year accuracy 45 / 80 met price target | 25%upside $7 | Sector Perform Maintained | 4 Oct 2024 |
Oppenheimer Jay Olson 27% 1-year accuracy 13 / 48 met price target | 488%upside $33 | Outperform Maintained | 12 Aug 2024 |
RBC Capital Gregory Renza 56% 1-year accuracy 45 / 80 met price target | 43%upside $8 | Sector Perform Maintained | 9 Aug 2024 |
Financial journalist opinion
Based on 3 articles about INO published over the past 30 days